New drug cocktail aims to tackle tough blood cancers
NCT ID NCT03136146
First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or not responded to treatment. The study will enroll 42 participants to evaluate side effects and how well the treatment works. The goal is to find a more effective option for these hard-to-treat blood cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, bortezomib
- What this could lead to
- If successful, this could provide a new treatment option for patients with hard-to-treat leukemia or lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- This is a small, early-phase study (42 participants) focused on safety and response rate. The combination of multiple chemotherapy drugs may cause significant side effects, and it is not yet known if it will improve long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost chemo against tough lymphomas?
- Engineered immune cells take aim at tough childhood leukemia
- Selective immune cell removal may tame transplant complications
- Gene therapy takes on HIV and cancer in one shot
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- New drug cocktail aims to outsmart Hard-to-Treat lymphoma